Biofrontera AG: Notice of Annual Results 2016

Biofrontera AG / Biofrontera AG: Notice of Annual Results 2016 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Leverkusen, Germany, 07 April 2016 - Biofrontera AG (AIM: B8F), the specialist for sun-induced skin cancer, will be announcing its financial results for the twelve-month period ended 31 December 2015 on 15 April 2016.
 
Conference calls for shareholders and interested investors will be held on 15 April 2016 at the following times:
 
10.00am CET (4.00am EDT) conference call in German:
Dial-in number: [phone]
Conference code: 96247638#
 
2.30pm CET (8.30am EDT) conference call in English:
Dial-in number Germany: [phone]
Dial-in number UK: [phone]
Dial-in number USA: [phone]
Dial-in number USA (New York): [phone]
Conference code: 31292670#

Ends

Enquiries, please contact:

Biofrontera AG
Thomas Schaffer, Chief Financial Officer
[phone]
[e-mail]
www.biofrontera.com

IR and PR US: The Ruth Group

IR: Lee Roth / Tram Bui
[phone] / 7035

PR: Kirsten Thomas
[phone]

Background:

The Biofrontera Group (FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz^®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz^® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.
The company also markets the Belixos^® dermatological range of cosmetics. Belixos^® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos^® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire

HUG#2001462

--- End of Message ---

Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;